H.C. Wainwright Downgrades ZIOPHARM Oncology (ZIOP) to Neutral

H.C. Wainwright analyst Swayampakula Ramakanth downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from Buy to Neutral.

For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.

Shares of ZIOPHARM Oncology closed at $5.33 yesterday.

You May Also Be Interested In

• Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell
• Goldman Sachs Downgrades Mercialys (MERY:FP) (MEYIF) to Neutral
• Facebook (FB) PT Raised to $360 at Jefferies Into Q1 EPS, Sees Estimates as 'Too Conservative'